News | November 14, 2022
Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Results reinforce commitment to next-generation oral SERD development programme
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Subscribe To Our Newsletter & Stay Updated
